DNA Script vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
DNA Script has raised $335M total including a $165M oversubscribed Series C; received CE Mark in 2025 for SYNTAX System in clinical labs across Europe; developing enzymatic DNA synthesis printers that enable on-demand, benchtop DNA production for.
About
DNA Script is a biotechnology company founded in 2014 and headquartered in Paris, France (with US operations in South San Francisco), that has developed a breakthrough enzymatic DNA synthesis (EDS) platform. Traditional chemical-based DNA synthesis — the process of producing custom DNA sequences used in genomics, synthetic biology, diagnostics, and therapeutic development — relies on hazardous chemicals and generates significant toxic waste. DNA Script's approach replaces these chemicals with enzymes (specifically terminal deoxynucleotidyl transferase, or TdT), enabling faster, greener, and more scalable DNA production at the benchtop.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.